Skip to Content
Morningstar

Regeneron Pharmaceuticals Inc REGN

Morningstar Rating
Unlock
Stock XNAS Rating as of
$911.09 +11.38 (1.26%)
View Full Chart
As of Cboe BZX Real-Time Price Open
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Regeneron's Solid Immunology Drug Dupixent and Growing Oncology Pipeline Support a Narrow Moat

Karen Andersen

Regeneron has leveraged its monoclonal antibody research and development platform to become one of the few biotechs to emerge as a profitable commercial operation and establish a narrow moat. Lead drug Eylea has global sales around $9 billion annually and is approved for wet age-related macular degeneration and other eye-related indications. The drug remains well positioned, as its high-dose formulation should allow it to continue to hold strong market share against biosimilars and Roche's new branded drug, Vabysmo.

Read Full Report

Price vs Fair Value

View History
REGN is trading at a 20% premium.
Price
$900.16
Fair Value
$395.00
Uncertainty
Medium
1-Star Price
$8,941.40
5-Star Price
$222.00
Economic Moat
Tlccff
Capital Allocation
Pjcxldh

Bulls Say, Bears Say

Bulls

Eylea has become the leading franchise in wet AMD and other ophthalmology markets because of its similar efficacy and more convenient dosing regimen compared with Lucentis and Avastin.

Bears

Regeneron's Eylea is competing with Roche and Novartis in the ophthalmology market, and it could be vulnerable to biosimilars beginning in 2024 and Medicare negotiations in 2028.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if REGN is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$899.71
Day Range
$903.82–911.75
52-Week Range
$684.17–998.54
Bid/Ask
$910.33 / $911.52
Market Cap
$99.93 Bil
Volume/Avg
149,892 / 462,556

Key Statistics

Price/Earnings (Normalized)
20.42
Price/Sales
7.75
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
1.82%

Company Profile

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Core
Total Number of Employees
13,450
Website
https://www.regeneron.com

Competitors

Valuation

View More
Metric
REGN
NVS
RHHBY
Price/Earnings (Normalized)
 20.4213.9711.10
Price/Book Value
 3.774.175.52
Price/Sales
 7.754.262.89
Price/Cash Flow
 21.6813.6410.64
Price/Earnings
REGN
NVS
RHHBY

Financial Strength

Metric
REGN
NVS
RHHBY
Quick Ratio
 4.820.880.99
Current Ratio
 5.691.161.35
Interest Coverage
 51.7310.9414.93
Quick Ratio
REGN
NVS
RHHBY

Profitability

Metric
REGN
RHHBY
NVS
Return on Assets (Normalized)
 16.26%17.03%12.15%
Return on Equity (Normalized)
 20.84%53.42%27.10%
Return on Invested Capital (Normalized)
 17.27%26.30%17.72%
Return on Assets
REGN
RHHBY
NVS
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRJxzmlrhbxZvrq$557.8 Bil
VRTX
Vertex Pharmaceuticals IncCmfnkcsScjvz$103.3 Bil
MRNA
Moderna IncCzwgllmtqZnqh$38.8 Bil
ARGX
argenx SE ADRBmlxrgrfMndns$21.3 Bil
BNTX
BioNTech SE ADRTxnsqqsjXdw$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncXdpyjqhcsQggvmcg$18.4 Bil
BMRN
Biomarin Pharmaceutical IncDtfnhqqbPlzqmgl$17.0 Bil
RPRX
Royalty Pharma PLC Class ANhxzllyxmBwnbsg$12.4 Bil
INCY
Incyte CorpPxzwzyfnsWdrjfm$11.9 Bil

Sponsor Center